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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. It introduces the current best practice in histopathology and cytopathology as it pertains to
head and neck and thyroid cancers.
Recommendations
• Accurate diagnosis of the type of malignancy is a key component of effective management. (R)
• Surgeons and oncologists should understand the scope and limitations of cellular pathology in order to inform
multidisciplinary discussions. (R)
• A clinically suspected diagnosis of malignancy should be confirmed by biopsy or cytology before operation. (R)
• Cytopathological diagnoses should be discussed with surgeons and radiologists to maximise the information
gained from each modality of investigation. (R)
• Pathological investigations are the basis for accurate cancer staging and stratification of clinical outcomes. (R)
Introduction
This paper is an overview of the use of laboratory
investigations and focuses on the important elements
of cancer pathology reports that clinicians should use
when discussing the implications of a diagnosis and
management options with patients and with colleagues
in a multidisciplinary setting. The recommendations for
pathology practice are based on published evidence; key
references are provided in the World Health Organisation
(WHO) Classification of Tumours1 and in the series of
Histopathology Datasets published by the Royal
College of Pathologists.2,3 Pathologists have critically
important roles in confirming or excluding specific dis-
eases on the basis of cytology or diagnostic biopsy, in
assessing the adequacy of treatment, recognising key pre-
dictive and prognostic factors, and in contributing evi-
dence-based criteria for the appropriate stratification of
clinical outcomes.
Use of cellular pathology services
Frozen section
Patient management should be guided primarily by pre-
operative biopsy and/or fine needle aspiration (FNA)
cytology. Intra-operative frozen sections have a limited
role and are appropriately used for the assessment of
surgical excision margins when there is clinical doubt
as to adequacy.4 Frozen sections are occasionally used
to confirm the diagnosis of branchial cleft cysts in
older people, of papillary, medullary or anaplastic
thyroid carcinomas5 or to identify lymph node involve-
ment in thyroid cancers; they should not be used to dif-
ferentiate follicular thyroid carcinoma from adenoma or
follicular variant papillary carcinoma. It should be
appreciated that the quality of frozen sections is not as
good as paraffin sections and that important information
may be missed or destroyed through inappropriate use of
frozen sections, particularly if small pieces of tissue are
submitted for examination.
Definitive operative specimen
Specimens should be submitted in an adequate
amount of 10 per cent neutral buffered formalin (at
least three times the volume of the specimen) unless
there is prior agreement with the laboratory.2 The
site and nature of each specimen should be clearly
described on the request form and should be appropri-
ately orientated. The form must include the clinical
indication for the operation, the duration of signs
and symptoms, pre-operative radiotherapy (RT) or
chemotherapy, and details of previous biopsies or
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cytological investigations, and relevant biochemistry
(particularly for thyroid diseases).
Lymph node specimens
The site of origin of lymph nodes should be recorded,
and formal neck dissections should clearly state which
nodal groups are included and should be clearly orien-
tated, preferably with a diagram.6 The optimal handling
of biopsies for suspected lymphoma should be dis-
cussed with the laboratory; it is often useful to collect
fresh tissue in a transport medium for possible cytogen-
etic and molecular studies.
The predictive value of sentinel node biopsy is now
recognised and is becoming established practice, particu-
larly for the early-stage oral carcinoma.7 The pathologic-
al assessment of sentinel nodes is highly demanding of
laboratory time and expertise, involving multiple sections
and immunocytochemistry.8 This should only be under-
taken if appropriately resourced.
Resection specimens including bone
When cancer resection specimens contain bone, it is
often possible to obtain a preliminary report on the
soft tissue components of the specimen while the
bone is decalcified before processing the tissues to
assess the extent of bone invasion and bony margins.
Decalcification may take several days or weeks
depending on the density of the bone.
Immunocytochemistry and molecular pathology
Immunocytochemistry plays an important role in the
correct diagnosis of primary head and neck cancers,
particularly for the less common entities. The prognos-
tic value of assessing oropharyngeal carcinomas for
evidence of human papilloma virus infection (HPV)
is established, with current guidance recommending a
combination of immunocytochemistry for p16 protein
overexpression and in situ hybridisation for high-risk
HPVDNA.Morphologically similar poorly differentiated
carcinomas arising in the oropharynx and nasopharynx,
and their nodal metastases may be distinguished by
the presence of HPV and Epstein–Barr virus DNA,
respectively.
In patients with metastatic malignancy in cervical
lymph nodes without evidence of primary disease,
the morphological features of the metastatic tumour
may be useful, e.g. thyroid and salivary neoplasms.
Immunocytochemical investigation of FNA or biopsy
material does not reliably distinguish between primary
sites of squamous cell carcinomas (SCCs) but may be
helpful in identifying adenocarcinomas arising in
the gastrointestinal tract, lungs or prostate. Clinicians
should note that immunocytochemical markers are very
rarely specific for particular tissues and that opinions on
likely primary sites are based on the assessment of a
panel of different markers and the balance of probabil-
ities. Clinical features, such as the pattern of nodal
disease, and imaging studies should be incorporated
into the multidisciplinary assessment of these patients.
Molecular genetic profiling of head and neck cancers
is not currently recommended outside the research
setting.2,9,10
Multidisciplinary team working
Cellular pathologists are core members of cancerMDTs
and are essential to the provision of a successful service.
The MDT should have a risk-based approach to devel-
oping its policy on pathology review, particularly for
patients who have had diagnostic biopsies in other hos-
pitals. Pathological review is essential for thyroid
cancers and is good practice for other situations.
Malignancies of the upper
aerodigestive tract
Squamous cell carcinoma
The initial diagnosis may be obvious clinically on the
basis of an irregularly infiltrating mass with ulceration,
but should always be confirmed by biopsy as some
inflammatory diseases, e.g. tuberculosis and sarcoidosis,
can mimic carcinomas clinically and other mucosal
malignancies, e.g. lymphoma, may require consideration
of other treatment options. Practical problems that may
preclude definitive diagnosis on diagnostic biopsies
include poor orientation, necrotic or inflammatory
debris, small samples containing few cells and crush
artefact. The edges of laser resection specimens often
show thermal artefacts, making detailed interpretation
impossible. Patients who have been treated with RT
and/or chemotherapy may have biopsies or resections
to assess any residual or recurrent disease at primary
or nodal sites. Extensive scarring, radiation-associated
nuclear atypia and loss of the normal anatomical land-
marks may make assessment of these specimens diffi-
cult. A good chemotherapeutic response may leave a
mass of necrotic tissue containing degenerate keratino-
cytes; viable carcinoma may not be identified even
after extensive histological sampling.
Morphological variants of SCC. Some variants of SCC
are associated with particular difficulties in diagnosis
and clinical assessment but should be managed, stage
for stage, in line with classical carcinomas.
Papillary SCC is typified by an exophytic growth
pattern with fronds of fibrovascular tissue covered by
squamous epithelium showing in situ carcinoma; areas
of invasive carcinoma are often small and limited in
extent. Diagnostic biopsies may show only in situ car-
cinoma despite a bulky tumour. The prognosis is rela-
tively good due to the limited invasive component.
Verrucous SCC has an exophytic growth and is
formed by extremely well-differentiated squamous epi-
thelium with minimal atypia and abundant surface
keratin. Diagnostic biopsies may not show invasion
and the minimal cellular atypia makes pathologists
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reluctant to diagnose malignancy. Repeated biopsies and
appreciation of the discrepancy between a clinically
obvious carcinoma and minimal microscopic atypia are
often needed to make a diagnosis of carcinoma.
Spindle cell carcinomas typically present as polypoid
tumours with an ulcerated surface and are formed by
sheets of atypical spindle cells, often raising the possibil-
ity of sarcoma. Sarcomas ofmucosal origin are extremely
rare in adults, but a definitive diagnosis of spindle cell car-
cinoma may only be possible on resection specimens
when small areas of in situ or more typical invasive car-
cinoma are identified. Immunohistochemistry only iden-
tifies squamous epithelial differentiation in about 60–70
per cent of cases.
Oropharyngeal SCCs are usually related to high-risk
HPV infection. Typical HPV-associated carcinomas
are non-keratinising (basaloid) carcinomas, but may
be of any histological type.
Information that should be provided in histopathology
reports. The information available from diagnostic
biopsies is limited but should normally include
whether any carcinoma is invasive or in situ and, for
invasive carcinomas, should provide a provisional esti-
mate of the degree of differentiation and the growth
pattern. In the oral cavity, the depth of invasion or
tissues involved (mucosa, muscle) may guide the
extent of surgery.
Resection specimens provide sufficient tissue to
describe the full range of prognostic information2,11
(Box I); the basis in evidence for this information is
provided in guidelines published by the Royal
College of Pathologists and varies between anatomical
sites.
BOX I
PROGNOSTIC INFORMATION DERIVED FROM
PRIMARY CARCINOMAS
Site and subsite
Histological type of carcinoma
Grade of differentiation
Growth pattern
Maximum diameter
Maximum depth of invasion
Invasion of lymphatic or blood vessels
Invasion of the peri-neural space of nerve trunks
Invasion of bone or cartilage
Distance of carcinoma from resection margins
Dysplasia and intra-epithelial neoplasia
Squamous cell carcinomas are the result of a combin-
ation of genetic mutations, some of which are manifest
in precursor lesions by atypia of the epithelial cells
collectively referred to as dysplasia or intra-epithelial
neoplasia. Severe cytological atypia is associated
with a high risk of progression to carcinoma and,
in resection specimens, its presence at resection
margins may predict local recurrence. The various,
commonly used, grading systems are summarised in
Table I and, although different criteria are used, each
seeks to place a particular abnormality in a continuous
spectrum of appearances from mild to severe atypia.
There is no UK consensus12 on which grading
system should be recommended, although a majority
of pathologists probably use the WHO dysplasia
system but regard severe dysplasia and in situ carcin-
oma as indistinguishable. A proposed consensus
system for laryngeal lesions based on the Ljubljana
classification13 is gaining recognition, but its transla-
tion to UK practice is limited. Management decisions
should take account of the microscopic severity of the
lesion and its clinically assessed extent.
Other mucosal malignancies
Adenocarcinomas. This may be of surface or salivary
type. Those derived from surface epithelium of the
nose and sinuses may resemble intestinal carcinomas
and have a relatively poor prognosis compared with
other low grade adenocarcinomas.
Sinonasal undifferentiated (anaplastic) carcinoma. This
is a rare, clinically aggressive neoplasm composed of
cells that are undifferentiated on routine stains but
which show varying degrees of neuroendocrine differ-
entiation on immunocytochemistry. These carcinomas
often result in bone destruction and extension into the
orbit or cranial cavity and have a poor prognosis
despite aggressive surgery and chemoradiotherapy.
Olfactory neuroblastoma (esthesioneuroblastoma). This
presents as a polypoid mass high in the nasal cavity.
The histological features are characteristic and immuno-
cytochemistry is positive for neuroendocrine markers.
Morphological grading systems are of limited prognos-
tic value. Despite spread to regional nodes and more
TABLE I
GRADING SYSTEMS FOR PRECURSOR LESIONS OF
SQUAMOUS EPITHELIAL MALIGNANCIES
WHO
Classification
2005
Squamous
intraepithelial
neoplasia (SIN)
Ljubljana
classification;
squamous
intraepithelial lesions
(SILs)
Squamous cell
hyperplasia
Simple hyperplasia
Mild dysplasia SIN 1 Basal/parabasal cell
hyperplasia
Moderate
dysplasia
SIN 2 Low grade SIL
Severe dysplasia SIN 3 High grade SIL
Carcinoma in
situ
SIN3 Carcinoma in situ
Note: The categories in the different systems are not strictly com-
parable as different morphological and architectural criteria are
used
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distant sites, prognosis is good with a 78 per cent five-
year survival after surgery and RT.
Malignant melanoma. This most often arises in the nasal
cavities and less often in the sinuses, presenting in
adults over 50 years as polypoid, friable haemorrhagic
masses. Histologically there is a wide range of appear-
ances with very variable melanin production (30 per
cent are amelanotic). Survival is poor with death due
to widespread metastasis and/or extensive local
recurrence.
Lymphomas. This may present as primary mucosal
malignancies in the sinonasal tract and tonsils. Almost
all are non-Hodgkin’s lymphomas with natural killer/
T-cell lymphomas mainly affecting the sinonasal tract
and B-cell lymphomas arising in the tonsils.
Nasopharyngeal carcinoma. This includes keratinising
SCCs and non-keratinising differentiated and undifferen-
tiated carcinomas and is usually related to Epstein–Barr
virus infection. The synonym of ‘lymphoepithelioma’
should not be used. Keratinising carcinomas are more
radioresistant than non-keratinising and undifferentiated
carcinomas.
Diagnosis and management of neck lumps
Fine needle aspiration
Fine needle aspiration (FNA) of tissue by a well-trained
operator is an essential part of the diagnostic assessment
of patients with neck or thyroid lumps and as part of
staging procedures for patients with the known head
and neck cancer.14,15 High-quality preparations are
essential for an effective service. Either rapidly air-
dried slides or needle washings into preservative
solution may be required depending on the clinical cir-
cumstance. The cytological diagnosis of metastatic
SCC in cervical nodes is usually straightforward, but
cystic metastases can be difficult to distinguish from
benign cystic lesions containing squamous cells such
as branchial cleft cysts; a high degree of clinical suspi-
cion for malignancy is required in older patients with
cystic lesions containing squamous cells. Haemorrhage
into cystic neck nodes may conceal underlying malig-
nancy, particularly metastatic papillary carcinoma from
the thyroid. Multidisciplinary correlation of findings is
of fundamental importance.
FNA cytology is the method of choice for monitor-
ing patients known to have lymphoma as cytology
can document disease recurrence and can indicate
transformation from low to high grade disease. The
primary diagnosis of lymphoma can be made from
FNA specimens if the laboratory repertoire includes
molecular techniques and flow cytometry. FNA
cytology is an effective method to triage patients into
those in whom significant disease can be excluded,
those in whom a definitive diagnosis of benign
disease or metastatic malignancy can be made, and
those with possible lymphoma who need lymph node
biopsy. Where malignancy is identified, additional
immunocytochemical andmolecular testing for planning
management is possible with appropriate specimen col-
lection procedures.
Neck dissections
The presence or absence of nodal metastasis is a key com-
ponent of tumour–node–metastasis (TNM)16 staging and
determines further management. The pathological assess-
ment of nodes in resection specimens verifies pre-opera-
tive imaging studies and identifies small volume nodal
disease that is beyond the resolution of current imaging
techniques.
The terminology of possible nodal involvement by
carcinoma includes:
• Isolated tumour cells (ITCs) – collections of cells
<0.2 mm diameter
• Micrometastasis – tumour deposits 0.2–2 mm in
diameter
• Conventional metastasis – a tumour deposit more
than 2 mm diameter
• Extracapsular spread – carcinoma extending
through a breach in the capsule from a lymph
node into surrounding connective tissue.
For TNM staging, the presence of ITCs is classified as
pN0 as their significance is unknown. Micrometastases
are recorded as pN1(mi), pN2b(mi) or pN2C according
to their extent in multiple nodes. Core pathological data
for nodal metastases are shown in Box II.
BOX II
PROGNOSTIC INFORMATION DERIVED FROM
LYMPH NODE EXCISIONS
Number of positive nodes
Sites of positive nodes
Size of largest metastasis
Presence or absence of extracapsular spread
Salivary neoplasms
Most tumours arising in the major or minor salivary
glands are benign (although the proportions vary from
site to site), but pre-operative suspicion of malignancy
may be raised on clinical examination, from imaging
studies or from pre-operative FNA cytology. All
tumours of the major salivary glands should have pre-
operative FNA cytology to guide treatment, which can
usually accurately diagnose pleomorphic salivary
adenoma and Warthin’s tumour with confidence, differ-
entiate benign neoplasms from malignant in 81–98 per
cent of cases, but which is less good at establishing a
specific type of carcinoma. The main categories of
salivary carcinoma are well defined, but these tumours
have many morphological variants and precise histo-
logical diagnosis often requires a specialist opinion.
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Many salivary neoplasms have characteristic genetic
translocations17 which aid diagnosis and may lead to
targeted therapeutics. The core pathological data from
salivary resections for neoplasia are shown in Box III.
BOX III
PROGNOSTIC INFORMATION DERIVED FROM
SALIVARY GLAND RESECTIONS
The histological type of neoplasm
(according to the WHO Classification)
The grade of malignancy (see text)
The distance to the resection margins
The presence or absence of peri-neural or vascular
invasion
The presence or absence of lymph node
involvement
Grading of the degree of malignancy is prognostically
useful for some salivary carcinomas. Grading of
mucoepidermoid carcinomas relates to metastatic
potential and survival, whichever grading system is
used. Acinic cell carcinomas are usually circumscribed
but incompletely encapsulated; grading on the basis of
cytological features is not generally useful, except for
rare tumours showing dedifferentiation. Assessment
of Ki-67 (MIB1) labelling is of prognostic value, and
acinic cell carcinomas with indices of >5 per cent
behaving more aggressively. The growth pattern of
adenoid cystic carcinoma is related to metastatic poten-
tial, with 0–4 per cent of cribriform, hyaline and
tubular carcinomas, and 33 per cent of solid (basaloid)
carcinomas metastasising to local lymph nodes. Distant
metastasis is more common in solid tumours. Salivary
duct carcinoma is a high-grade malignancy morpho-
logically resembling ductal carcinoma of the breast.
About 70 per cent express androgen receptors and
15 per cent express HER-2 (human epithelial growth
factor receptor 2); features which may influence
therapy. Carcinomas arising in pleomorphic adenomas
may be of any or mixed histological type; the extent of
invasion is prognostically useful as invasion more than
5–6 mm from the capsule of the residual adenoma is
associated with a high risk of local recurrence and
distant metastasis. Non-invasive or minimally invasive
carcinomas ex pleomorphic adenoma are true malig-
nancies, but have a very low rate of disease progression.
Thyroid cancers
Most lesions will have had FNA before surgery.
Immediate assessment of the adequacy of aspirates
may be helpful. The descriptive cytology report
informs clinical decisions on management and should
incorporate a categorical summary3,18 (Table II).
For all malignant thyroid tumours, the national
dataset for histopathology reports3 defines core data
items of prognosis importance that will allow TNM
staging16 (Box IV). Some histological variants of
thyroid carcinomas have prognostic importance. For
diagnostic purposes, oncocytic (Hürthle cell) follicular
tumours are regarded as a variant of follicular tumours
and the criteria for malignancy are the same. The pres-
ence of any poorly differentiated or anaplastic compo-
nent affects prognosis.3
BOX IV
PROGNOSTIC DATA FROM THYROID
RESECTION SPECIMENS
Histological type of malignancy
Whether carcinoma is unifocal or multifocal
Maximum dimension of carcinoma (largest if
multifocal)
Closest distance to surgical resection margin
(R status)
Extension into extrathyroidal tissues (macroscopic
or microscopic)
Presence of lymphatic or vascular invasion
Site and number of lymph nodes sampled and those
involved
Papillary carcinoma
A single papillary microcarcinoma (≤10 mm diameter)
discovered incidentally in a resection performed for
another disease is not thought to have a significant
risk of recurrence or metastasis. Some microcarcino-
mas are potentially more aggressive including those
with multifocal disease, extrathyroid extension and
lymphatic invasion.
Tall cell and columnar variants of papillary carcin-
oma may be more aggressive, while the outcome of
the diffuse sclerosing variant is a matter of debate.
Diagnosis of the follicular variant of papillary car-
cinoma (FVPC) may be difficult and require specialist
opinion. The non-encapsulated invasive FVPC has a
metastatic potential similar to that of classical papillary
carcinoma, while encapsulated FVPC has metastatic
potential related to the number of foci of vascular
invasion.
TABLE II
CATEGORISATION OF THYROID FNAS WITH
LIKELIHOOD OF MALIGNANCY (LOM) (RCPATH AND
BSCC GUIDELINES)
Thy 1 Non-diagnostic for cytological
diagnosis
LOM 0–10%
Thy 1c Non-diagnostic for cytological
diagnosis – cystic lesion
Thy 2 Non-neoplastic LOM 0–3%
Thy 2c Non-neoplastic, cystic lesion
Thy 3a Neoplasm possible – atypia/non-
diagnostic
LOM 5–15%
Thy 3f Neoplasm possible, suggesting
follicular neoplasm
LOM 15–30%
Thy 4 Suspicious of malignancy LOM 60–75%
Thy 5 Malignant LOM 97–100%
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Follicular carcinoma
A follicular neoplasm is defined as carcinoma on the
basis of capsular and/or vascular invasion. Minimally
invasive follicular carcinomas show only focal micro-
scopic vascular and/or capsular invasion. Tumours
showing only capsular invasion have a minimal risk of
metastasis. The risk of metastasis increases with vascular
invasion, but no significance is attached to the number of
foci of vascular invasion. Widely invasive follicular car-
cinoma shows obvious gross invasion or extensive
microscopic infiltration of thyroid parenchyma, vessels
or extrathyroidal tissues. The number of foci of vascular
invasion should be described but is not prognostically
significant.
Medullary carcinoma
The diagnosis should be confirmed by calcitonin
immunoreactivity, although some poorly differentiated
carcinomas only express carcinoembryonic antigen
(CEA). Although there are variations in the cellular
pattern and presence of amyloid these are unimportant
prognostically compared with the tumour stage and
completeness of excision. In the syndromes of multiple
endocrine neoplasia type 2 and familial medullary
thyroid carcinoma, medullary carcinoma is often multi-
focal and preceded and/or accompanied by C-cell
hyperplasia. Genetic testing for RET mutations will
detect familial syndromes.
Poorly differentiated carcinoma
This group is defined as follicular or papillary carcin-
oma with necrosis and/or a mitotic count of five or
more in ten high-power microscopic fields. The
growth pattern may be insular, trabecular or solid.
Poorly differentiated carcinomas have a poorer progno-
sis than differentiated carcinomas with variable
response to radio-iodine treatment.
Undifferentiated/anaplastic carcinoma
Anaplastic carcinoma is diagnosed where a follicular or
papillary carcinoma shows even a minor undifferenti-
ated (anaplastic) component. Most undifferentiated
tumours will be diagnosed by FNA cytology, core or
open biopsy and will not have a surgical resection.
The report should describe how immunocytochemistry
has been used to exclude other poorly differentiated
malignancies, especially lymphoma.
Lymphoma
The diagnosis of thyroid lymphoma is usually made on
core or open biopsy rather than resection specimens
and may require extensive immunocytochemical and
molecular testing. It is important to distinguish
between primary thyroid lymphoma and involvement
of the thyroid by lymphoma as part of a wider disease.
Recommendations
• Accurate diagnosis of the type of malignancy
is a key component of effective management
(R).
• Surgeons and oncologists should understand
the scope and limitations of cellular pathology
in order to inform multidisciplinary
discussions (R)
• A clinically suspected diagnosis of malignancy
should be confirmed by biopsy or cytology
before operation (R)
• Cytopathological diagnoses should be
discussed with surgeons and radiologists to
maximise the information gained from each
modality of investigation (R)
• Pathological investigations are the basis for
accurate cancer staging and stratification of
clinical outcomes (R)
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